AIM:To evaluate the efficacy of treating traumatic optic neuropathy( TON) with mouse nerve growth factor. METHODS: We searched the Cochrane Library, Pubmed, Medline, CNKI, Wanfang database and VIP to collect randomized controlled trials ( RCTs ) of using mouse nerve growth factor for TON. The quality of the included trials was assessed and poor-qualified trials were eliminated before the meta - analysis was conducted. RESULTS:Seven RCTs with a total of 399 eyes included were retrieved, and OR=3. 78 with a 95%CI of [ 2. 35, 6.06], the difference was significant (P<0. 01). CONCLUSION:The existing evidence supports that the prognosis of TON is better when mouse nerve growth factor are adopted in treatment, but there is still a need for well-planned, large-scale and multicenter RCTs to verify it.%目的：系统评价鼠神经生长因子治疗外伤性视神经病变的临床效果。 方法：计算机检索 Cochrane Library、Pubmed、Medline、中国数字医院图书馆(www. chkd. cnki. net)全文数据库、万方数据库、中文科技期刊全文数据库( VIP),检索时间为建库至2014-01,并辅以手工检索,全面收集有关鼠神经生长因子治疗外伤性视神经病变的对照研究,评价纳入研究质量,提取有效数据,并进行Meta分析。 结果：符合纳入标准的对照试验文献7篇,合计399眼,鼠神经生长因子参与治疗后,优势比OR=3.78,95%CI为[2.35,6.06],P<0.01,差异具有统计学意义。 结论：从现有的临床证据来看,鼠神经生长因子参与治疗能提高外伤性视神经病变的治疗有效率。但还需要更多高质量的多中心、随机、双盲临床试验来进一步验证和支持。
展开▼
